Moreover, ACE2 showed significant expression differences between sexes in bladder urothelial carcinoma, head and neck squamous cell carcinoma, and kidney renal clear cell carcinoma (Figure 1F, P < 0.05). This evidence concerns the gene ACE2 and bladder transitional cell carcinoma.